News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Pfizer Inc.'s Temsirolimus Plus Roche’s Bevacizumab Not Recommended for First-Line RCC
July 12, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CHICAGO (EGMN) – The combination of two standard treatments, temsirolimus and bevacizumab, dramatically increased toxicity without any signal of increased efficacy in the first-line treatment of metastatic kidney cancer in the phase II TORAVA trial.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Pfizer
Roche
MORE ON THIS TOPIC
Earnings
As Biogen Nears Presymptomatic Alzheimer’s Readout for Leqembi, Can Doctors Be Convinced?
October 30, 2025
·
2 min read
·
Annalee Armstrong
IN PARTNERSHIP WITH ELEMENT
Innovation, Resilience, and the Future of Global Manufacturing
October 30, 2025
·
1 min read
·
BioSpace Insights
CAR-T
Kyverna’s CAR T Therapy Sets ‘New Efficacy Standard’ in Myasthenia Gravis, De-Risking Phase III Trials
October 30, 2025
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Novartis Presents New Data From Potential First Targeted Sjögren’s Treatment
October 29, 2025
·
3 min read
·
Heather McKenzie
